Imaging Biomarkers in Preclinical and Symptomatic AD. (ACS PiB IND)
Tammie L. S. Benzinger, MD, PhD
Summary
The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).
Description
This study will use a radioactive tracer called \[11C\]-Pittsburgh Compound B (11C\]PIB), which is a tracer that binds to beta amyloid protein in the brain. This compound is considered investigational, which means that it has not been approved by the United States Food and Drug Administration (FDA).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female, any race; * Age ≥ 18 years; * Active participants currently enrolled in the Knight Alzheimer's Disease Research Center (ADRC) at Washington University. Exclusion Criteria: * Hypersensitivity to \[11C\] PIB or any of its excipients; * Contraindications to PET, CT or MRI (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate; * Severe claustrophobia; * Women who are pregnant or breast-feeding will be excluded from PIB PET participation; * Has any condition that, in the opinion o…
Interventions
- Drug[11C] Pittsburgh Compound-B (PIB)
Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.
Location
- Washington University School of MedicineSt Louis, Missouri